Galmed Pharmaceuticals Stock Price Prediction

GLMD Stock  USD 0.40  0.04  11.11%   
The RSI of Galmed Pharmaceuticals' the stock price is about 63. This usually indicates that the stock is rather overbought by investors at the present time. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Galmed, making its price go up or down.

Oversold Vs Overbought

63

 
Oversold
 
Overbought
Galmed Pharmaceuticals stock price prediction is an act of determining the future value of Galmed Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Galmed Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Galmed Pharmaceuticals and does not consider all of the tangible or intangible factors available from Galmed Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Galmed Pharmaceuticals, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Galmed Pharmaceuticals' stock price prediction:
EPS Estimate Current Year
(1.29)
EPS Estimate Next Year
(1.03)
Wall Street Target Price
1
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Galmed Pharmaceuticals based on different types of headlines from major news networks to social media. The Galmed stock price prediction module provides an analysis of price elasticity to changes in media outlook on Galmed Pharmaceuticals over a specific investment horizon. Using Galmed Pharmaceuticals hype-based prediction, you can estimate the value of Galmed Pharmaceuticals from the perspective of Galmed Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Galmed Pharmaceuticals. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Galmed Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Galmed because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Galmed Pharmaceuticals after-hype prediction price

    
  USD 0.4  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Galmed Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Galmed Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.061.286.03
Details
Naive
Forecast
LowNextHigh
0.010.355.09
Details
1 Analysts
Consensus
LowTargetHigh
3.644.004.44
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.32-0.32-0.32
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Galmed Pharmaceuticals. Your research has to be compared to or analyzed against Galmed Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Galmed Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Galmed Pharmaceuticals.

Galmed Pharmaceuticals After-Hype Price Prediction Density Analysis

As far as predicting the price of Galmed Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Galmed Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Galmed Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Galmed Pharmaceuticals Estimiated After-Hype Price Volatility

In the context of predicting Galmed Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Galmed Pharmaceuticals' historical news coverage. Galmed Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.02 and 5.15, respectively. We have considered Galmed Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.40
0.40
After-hype Price
5.15
Upside
Galmed Pharmaceuticals is dangerous at this time. Analysis and calculation of next after-hype price of Galmed Pharmaceuticals is based on 3 months time horizon.

Galmed Pharmaceuticals Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Galmed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Galmed Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Galmed Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.19 
4.75
 0.00  
  0.01 
7 Events / Month
10 Events / Month
In about 7 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.40
0.40
0.00 
47,500  
Notes

Galmed Pharmaceuticals Hype Timeline

Galmed Pharmaceuticals is currently traded for 0.40. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.01. Galmed is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is expected to be very small, whereas the daily expected return is currently at 0.19%. %. The volatility of related hype on Galmed Pharmaceuticals is about 11014.49%, with the expected price after the next announcement by competition of 0.39. The company has price-to-book (P/B) ratio of 0.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Galmed Pharmaceuticals recorded a loss per share of 2.5. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 15th of May 2023. Given the investment horizon of 90 days the next expected press release will be in about 7 days.
Check out Galmed Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.

Galmed Pharmaceuticals Related Hype Analysis

Having access to credible news sources related to Galmed Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Galmed Pharmaceuticals' future price movements. Getting to know how Galmed Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Galmed Pharmaceuticals may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
EVFMDEvofem Biosciences 0.00 0 per month 0.00 (0.18) 16.28 (21.87) 51.24 
AFMDAffimed NV(0.05)3 per month 0.00 (0.02) 7.84 (8.62) 26.09 
ABEOAbeona Therapeutics(0.91)8 per month 0.00 (0.02) 8.32 (7.63) 36.43 
AKBAAkebia Ther(0.20)7 per month 5.03  0.01  11.18 (8.38) 42.39 
KODKodiak Sciences(0.11)8 per month 7.50  0.04  12.45 (10.92) 58.01 
MREOMereo BioPharma Group(0.12)6 per month 0.00 (0.05) 7.69 (6.07) 21.23 
ADVMAdverum Biotechnologies 1.50 10 per month 5.78  0.08  15.08 (7.88) 64.40 
ADAPAdaptimmune Therapeutics Plc(0.02)7 per month 5.28  0.13  12.87 (9.09) 31.05 
PIRSPieris Pharmaceuticals(0.54)1 per month 0.00 (0.03) 5.91 (5.42) 33.39 
PDSBPDS Biotechnology Corp(0.03)7 per month 0.00 (0.08) 10.11 (9.16) 26.33 
LPTXLeap Therapeutics(0.06)8 per month 4.67  0.02  12.10 (8.02) 43.02 
FBIOFortress Biotech(0.01)9 per month 3.93 (0.01) 10.10 (7.03) 24.66 
MBIOMustang Bio(0.10)6 per month 0.00 (0.28) 8.57 (11.11) 36.13 
ACHLAchilles Therapeutics PLC(0.02)10 per month 6.04  0  9.56 (9.02) 38.89 
APTOAptose Biosciences(0.02)10 per month 0.00 (0.21) 7.92 (6.25) 19.67 
FBIOPFortress Biotech Pref 0.00 0 per month 3.37  0.02  3.71 (4.16) 22.88 

Galmed Pharmaceuticals Additional Predictive Modules

Most predictive techniques to examine Galmed price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Galmed using various technical indicators. When you analyze Galmed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Galmed Pharmaceuticals Predictive Indicators

The successful prediction of Galmed Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Galmed Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Galmed Pharmaceuticals based on analysis of Galmed Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Galmed Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Galmed Pharmaceuticals's related companies.
 2023 2024 (projected)
Graham Number16.7815.94
Receivables Turnover35.9637.76

Story Coverage note for Galmed Pharmaceuticals

The number of cover stories for Galmed Pharmaceuticals depends on current market conditions and Galmed Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Galmed Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Galmed Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Galmed Pharmaceuticals Short Properties

Galmed Pharmaceuticals' future price predictability will typically decrease when Galmed Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Galmed Pharmaceuticals often depends not only on the future outlook of the potential Galmed Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Galmed Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding2.8 M
Cash And Short Term Investments12.8 M
When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:
Check out Galmed Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Galmed Stock analysis

When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stocks Directory
Find actively traded stocks across global markets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Is Galmed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.50)
Return On Assets
(0.28)
Return On Equity
(0.51)
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.